Summary
A wide range of experimental evidence shows that bronchial eosinophilic inflammation plays a major role in the pathogenesis of the asthmatic syndromes characterised by reversible airway obstruction and bronchial hyperresponsiveness. A treatment aimed at controlling inflammation is therefore of primary importance in these pathological conditions. To date, corticosteroids have been routinely used for this purpose, but their administration is often accompanied by serious side effects. Cromoglycate and cromoglycate-like compounds have been proposed as alternative anti-inflammatory agents, but because their anti-inflammatory activity is relatively low, they can replace corticosteroids only in mild asthma. In the most severe forms of asthma, gold salts and methotrexate have demonstrated a steroid-sparing effect, but at the cost of a high incidence of toxic effects.
Little attention has been devoted to the use of NSAIDs in asthma for 2 principal reasons. In acute studies, NSAIDs such as aspirin (acetylsalicylic acid) and indomethacin have not shown satisfactory bronchodilator or antireactive activity. More importantly, NSAIDs have traditionally been associated with a relatively high frequency of severe obstructive reactions in patients with asthma.
However, nimesulide, a recently developed NSAID, has proven to be safe in NSAID-sensitive patients. Moreover, in guinea-pigs, the drug exhibits good antianaphylactic activity and an impressive antihistaminic effect that is not shared by other NSAIDs such as indomethacin. On the basis of these findings, nimesulide can be considered as a potential antireactive-antiasthmatic agent, of which further clinical investigation is justified.
Similar content being viewed by others
References
Balfour-Lynn L. Growth retardation in asthmatic children treated with inhaled beclomethasone dipropionate. Lancet 1: 115–116, 1988
Barnes PJ. New concepts in the pathogenesis of bronchial hyperresponsiveness and asthma. Journal of Allergy and Clinical Immunology 83: 1013–1026, 1989
Beasley R, Roche WR, Roberts JA, Holgate ST. Cellular events in the bronchi in mild asthma and after bronchial provocation. American Review of Respiratory Disease 139: 806–817, 1989
Bernstein DI, Bernstein JL, Bodenheimer SS, Pietrusko RG. An open study of auranofin in the treatment of steroid-dependent asthma. Journal of Allergy and Clinical Immunology 81: 6–16, 1988
Berti F, Rossoni G, Buschi A, Robuschi M, Villa LM. Antianaphylactic and antihistaminic activity of the non-steroidal antiinflammatory compound nimesulide in guinea pig. Arzeimittel Forschung/Drug Research 110: 1011–1016, 1990
Bianco S. Asthme et médicaments antiinflammatoires non stéroidiens. In Charpin S (Ed.) Allergologie, 2nd ed., pp. 683–693, Flammarion, Paris, 1986
Bianco S, Del Bono N, Grassi V, Orefice U. Effectiveness of nedocromil sodium versus placebo as additions to routine asthma maintenance therapy: a multicentre, double-blind, group comparative trial. Respiration 56: 204–211, 1989
Bianco S, Robuschi M, Damonte C, Simone P, Vaghi A, et al. Bronchial response to non-steroidal antiinflammatory drugs in asthmatic patients. Progress in Biochemical Pharmacology 20: 132–142, 1985
Bianco S, Robuschi M, Sestini P, Vaghi A, Refini RM, et al. Osmolarity and bronchial reactivity: the protective effect of loop diuretics. In Melillo G, et al. (Eds) Respiratory allergy, pp. 119–130, Decker Inc., Toronto, 1990
Boulet LP, Cartier A, Cockcroft DW, Gruber JM, Laberge F, et al. Tolerance to reduction in oral steroid dosage in severely asthmatic patients receiving nedocromil sodium. Respiratory Medicine 84: 317–323, 1990
Bousquet J, Chanez P, Lacoste JY, Barneon G, Ghavanian N, et al. Eosinophilic inflammation in asthma. New England Journal of Medicine 323: 1033–1039, 1990
Britton M, Earnshaw JS, Palmer JBD. On behalf of a European Study Group. Salmeterol. A new long acting β2-agonist. A twelve month comparison with salbutamol in asthmatic patients. Lancet, in press
Charous BL, Milwaukee MD. An open study of hydroxychloroquine (HCQ) in the treatment of severe symptomatic or corticosteroid-dependent asthma. Journal of Allergy and Clinical Immunology 85: 192, 1990
Chung KF, Ukema D, Yukawa T, Kroegel C, Chanez P, et al. Functional characteristics of beta adrenergic receptors of the intact eosinophil. Clinical Sciences 76 (Suppl. 20): 149, 1989
Cirillo R, Triggiani M, Siri L, Ciccarelli A, Pettit GR, et al. Cyclosporin A rapidly inhibits mediator release from human basophils presumably by interacting with cyclophillin. Journal of Immunology 144: 3891–3897, 1990
Cott GR, Chermiak RM. Steroid and steroid sparing agents in asthma. New England Journal of Medicine 318: 634–636, 1988
Cutz E, Levinson H, Cooper DM. Ultrastructure of airways in children with asthma. Histopathology 2: 407–421, 1978
Djukanovic R, Roche WR, Wilson JW, Beasley CRW, Twentyman OP, et al. Mucosal inflammation in asthma. American Review of Respiratory Disease 142: 434–457, 1990
Dunnill MS. The pathology of asthma with special reference to changes in bronchial mucosa. Journal of Clinical Pathology 13: 27–33, 1960
Editorial, β2-agonists in asthma: relief prevention morbidity. Lancet 336: 1411–1412, 1990
Fairfax AJ. Inhibition of the late asthmatic response to house dust mite by non-steroidal antiinflammatory drugs. Prostaglandins, Leukotrienes and Medicine 8: 239–248, 1982
Ferter D, Wanner A. Methotrexate: does it treat or reduce asthma. American Review of Respiratory Disease 143: 1–2, 1991
Finnerty PJ, Holgate ST. Evidence for the role of histamine and prostaglandins as mediators in exercise-induced asthma: the inhibitory effect of terfenadine and flurbiprofen alone and in combination. European Respiratory Journal 3: 540–547, 1990
Fish JE, Ankin MG, Adkinson Jr NF, Peterman VI. Indomethacin modification of immediate immunologic airway responses in allergic asthmatic and nonasthmatic subjects. Evidence for altered arachidonic acid metabolism in asthma. American Review of Respiratory Disease 123: 609–614, 1981
Hamid M, Rafferty P, Holgate ST. The inhibitory effect of terfenadine and flurbiprofen on early- and late-phase bronchoconstriction following allergen challenge in atopic asthma. Clinical and Experimental Allergy 20: 261–267, 1990
Israel E, Dermarkarian R, Rosenberg M, Sperling R, Taylor G, et al. The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air. New England Journal of Medicine 323: 1740–1744, 1990
Jones G, Mierins E, Karsh J. Methotrexate-induced asthma. American Review of Respiratory Disease 143: 179–181, 1991
Josephs LK, Gregg I, Muller MA, Holgate ST. Nonspecific bronchial reactivity and its relationship to the clinical expression of asthma. A longtitudinal study. American Review of Respiratory Disease 140: 350–357, 1989
Juniper EF, Frith PA, Hargreave FE. Airway responsiveness to histamine and methacholine: relationship to minimum treatment to control symptoms of asthma. Thorax 36: 575–579, 1981
Kirby JG, Hargreave FE, Cockcroft DW, O’Byrne PM. Effect of indomethacin on allergen-induced asthmatic response. Journal of Applied Physiology 66: 578–583, 1989
Laitinen LA, Heino M, Laitinen A, Kava T, Haahtela. Damage of airway epithelium and bronchial reactivity in patients with asthma. American Review of Respiratory Disease 131: 599–606, 1985
Manning PJ, Jones GL, O’Byrne PH. Tachyphylaxis to inhaled histamine in asthmatic subjects. Journal of Applied Physiology 63: 842–846, 1987
Manning PJ, Watson RM, Margolskee DJ, Williams VC, Schwartz JI, et al. Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4-receptor antagonist. New England Journal of Medicine 323: 1736–1739, 1990
Mapp CE, Boschetto P, Milani GF, Pivirotto F, Terazzin V, et al. Pathogenesis of late asthmatic reactions induced by exposure to isocyanates. Clinical Respiratory Physiology 23: 583–586, 1987
Margolskee DJ, Bigby BG, Boushey HA. Indomethacin blocks airway tolerance to repetitive exercise but not to eucapnic hy-perpnea in asthmatic subjects. American Review of Respiratory Disease 137: 842–846, 1988
Mattoli S, Foresi A, Carbo GM, Valente S, Ciappi G. The effect of indomethacin on the refractory period occurring after the inhalation of ultrasonically nebulized distilled water. Journal of Allergy and Clinical Immunology 79: 678–683, 1987
Moneret-Vautrin DA, Martin R. Intolerance to aspirin: a role for free radicals. Lancet 1: 929, 1985
Mullarkey MF, Lammert JK, Blumenstein BA. Long-term methotrexate treatment in corticosteroid-dependent asthma. Annals of Internal Medicine 112: 577–581, 1990
O’Byrne PH, Jones GL. The effect of indomethacin on exerciseinduced bronchoconstriction and refractoriness after exercise. American Review of Respiratory Disease 134: 69–72, 1986
Reid DM, Nicoll JJ, Smith MA, Higgins B, Tothul P, et al. Corticosteroids and bone mass in asthma: comparison with rheumatoid arthritis and polymyalgia rheumatica. British Medical Journal 293: 1463–1466, 1986
Robuschi M. Control of the bronchial tone. Respiration 54 (Suppl. 1): 100–107, 1988
Robuschi M, Spagnotto S, Gambaro G, Negretto G, Petrigni G, et al. Tromboxano A2 e reattività bronchiale all’aspirina. Lotta contro la TBC e malattie polmonari sociali 59: 81–85, 1989
Schwarz YA, Kivity S, Ilfeld DN, Schlesinger M, Greif J, et al. A clinical and immunologic study of colchicine in asthma. Journal of Allergy and Clinical Immunology 85: 578–584, 1980
Sears MR, Taylor DR, Print CG, Lake DG, Qingqing LI, et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 336: 1391–1396, 1990
Sestini P, Collodoro A, Pucci L, Pieroni MG, Refini RM, et al. Selective bronchial lavage in asthma. In Olivieri D, Bianco S (Eds) Airway obstruction and inflammation. Progress in Respiration Research, Vol. 24, pp. 46–50, Karger, 1990
Shiner RJ, Nunn RJ, Fan Chung K, Geddes DM. Randomized, double-blind, placebo controlled trial of methotrexate in steroid-dependent asthma. Lancet 336: 137–140, 1990
Sladek K, Dworsky R, Fitzgerald GA, Buitkus KL, Block FJ, et al. Allergen stimulated release of thromboxane A2 and leukotriene E4 in humans. American Review of Respiratory Disease 141: 1441–1445, 1990
Smith LJ, Kern R, Patterson R, Krell RD, Berstein PR. Mechanism of leukotriene D4-inducedd bronchoconstriction in normal subjects. Journal of Allergy and Clinical Immunology 80: 338–345, 1987
Vaghi A, Robuschi M, Pieroni MG, Banfi P, Berni F, et al. L’acetilsalicilato di lisina ma non il salicilato protegge dal broncospasmo da H2O. III Conferenza Italiana di Medicina Respiratoria. Abstracts. Torino-Milano, p. 18, 18–23 ottobre, 1990
Venge P. What is the role of eosinophils? Thorax 45: 161–163, 1990
Wald JA, Friedman BF, Farr RS. An improved protocol for the use of troleandomycin in the treatment of steroid-requiring asthma. Journal of Allergy and Clinical Immunology 78: 36–43, 1986
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bianco, S., Robuschi, M., Gambaro, G. et al. Bronchial Inflammation and NSAIDs. Drug Invest 3 (Suppl 2), 33–38 (1991). https://doi.org/10.1007/BF03258316
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03258316